Compare Novartis AG (NVS) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Toyota Motor Corp — how do they compare? Novartis AG trades at $143.44 (market cap $268.57B), while Toyota Motor Corp trades at $184.54 (market cap $217.38B). The key difference: Novartis AG is the larger of the two by market cap, and Toyota Motor Corp pays the higher dividend (3.37%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Toyota Motor Corp for 116 Days on average.
| NVS | TM | |
|---|---|---|
Market Cap | $268.57B | $217.38B |
Volume | 1,532,573 | 291,250 |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $248.29 |
52-Week Low | $121.80 | $166.50 |
Typical Hold Time | 82 Days | 116 Days |
Enterprise Value | $309.89B | $410.96B |
Dividend Yield | 3.31% | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Toyota Motor trades at $185.17, up 1.24% with a bearish technical signal despite strong fundamentals. The stock shows attractive valuation metrics with a P/E of 8.38 and P/S of 0.73, while delivering consistent earnings beats in recent quarters. Recent news highlights strong U.S. sales performance and electrification progress, though technical indicators show selling pressure with key support at $184.
Toyota presents a value opportunity with solid profitability and clean balance sheet, though near-term headwinds include China sales weakness and production disruptions. Analyst consensus leans cautious with 62.5% hold ratings, reflecting concerns about profit margin compression despite the company's market leadership and electrification investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
